Study looks at how cost-effective 2 drugs that prevent stroke are from a patient's viewpoint.
Too often in healthcare, the main concern of insurers and health professionals becomes focused on financial optimization over patient benefit. A recent University of Michigan Medical School study analyzed the true cost-effectiveness between 2 stroke medications: from the viewpoint of society and the insurer and from the viewpoint of the patient. The 2 drugs were dabigatran, a powerful but expensive therapy, and warfarin, a much cheaper but also less effective therapy.
The study analyzed findings from previous studies about the use of the 2 drugs in patients over the age of 65 years who had atrial fibrillation, increased risk of stroke, Medicare coverage, and no contraindications to anticoagulants. Quality-adjusted life expectancy, net costs, and adverse event risks were calculated for 35 years or until death by each payer perspective: society, Medicare, and the patient. The incremental cost-effective ratio (ICER) was the variable of comparison. A “cost-saving” ICER occurred when quality-adjusted life years outweighed overall costs.
Results showed that dabigatran is more cost-effective than warfarin from societal and Medicare perspectives, but when it comes to the patient’s perspective, it’s not so clear cut. For patients with Medicare Part D prescription drug coverage, dabigatran was cost-saving, but for patients without insurance the treatment was more costly. In other words, those without coverage would have to pay more than the worth of the therapeutic benefit they would receive from the drug. Adults without Medicare Part D coverage represents a sizeable percentage of the population, with vulnerability to the high costs of newer, more effective medications like dabigatran.
The study results demonstrate the idea that prescription coverage has a significant effect on what therapies are most cost-effective for patients. It all comes down to whether the cost of the medication (associated with insurance coverage) is worth the quality years a patient can gain (associated with patient’s risk of stroke).
With so many benefit/risk calculations to consider when it comes to choosing a medication, patients can become overwhelmed. Therefore, doctors and patients need to collaborate to choose therapies based on individual circumstances and coverage.
The patient-centered approach from this study can also be utilized to study other drugs on the market that have cheaper alternatives or more effective counterparts in order to decide the best treatment for the patient.
“The patient needs to be an important part of the decision about which anticoagulant strategy to choose,” the study’s lead author Geoff Barnes, MD, MSc, said in a statement. “If they don’t know what it will cost them, they can’t make an informed decision. Based on this study, we can give patients and physicians good cost-benefit data to use in that discussion.”
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More